Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALT-2074 in T2DM with CAD and Hp 2-2 Genotype
NCT00491543Phase 2Completed
- Sponsor
- Synvista Therapeutics, Inc.
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of alt-2074 in type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) (4 arms), sponsored by Synvista Therapeutics, Inc. Primary endpoints: Biomarkers of inflammation and oxidative stress at 28 days, Safety at 28 days and 1 more. Started Jun 2007; status: completed.
02
Drugs
alt-2074
03
Conditions
type 2 diabetes mellitus (T2DM)coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT00491543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00491543.